VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LLY
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LLYEli Lilly and Company
$1415.55$1.33T
Overview & Tools
OverviewChart Terminal ↗AnalysisVisualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksLLYBalance Sheet

Eli Lilly and Company (LLY) Balance Sheet

30Y historyFree accessUpdated daily

Total debt rose to $49.5B from $31.1B in 2024Q3 and debt-to-equity peaked at 2.43 before easing to 1.23, suggesting leverage is improving as the equity base rebuilds, though the thin $4.9B cash buffer warrants attention.

Income StatementBalance SheetCash FlowRatios

LLY Balance Sheet

Annual statement

LLY Balance Sheet

Eli Lilly and Company (LLY) balance sheet — 30-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Total Current Assets65.26B55.63B32.74B25.73B18.03B18.45B17.46B13.71B20.55B19.2B15.1B12.57B11.93B13.1B13.04B14.25B14.84B12.49B12.45B12.32B9.69B10.8B12.84B8.76B7.8B6.94B7.94B7.06B5.41B5.32B3.89B
Cash & Short-Term Investments4.88B7.27B3.42B2.93B2.21B3.91B3.68B2.44B7.41B8.03B6.04B4.45B4.83B5.4B5.68B6.9B6.73B4.5B5.93B4.83B3.89B5.04B7.46B3.71B3.65B3.73B4.62B3.84B1.5B1.95B813.7M
Cash Only4.88B7.16B3.27B2.82B2.07B3.82B3.66B2.34B7.32B6.54B4.58B3.67B3.87B3.83B4.02B5.92B5.99B4.46B5.5B3.22B3.11B3.01B5.37B2.76B1.95B2.7B4.11B3.7B1.5B1.95B813.7M
Short-Term Investments0105M154.8M109.1M144.8M90.1M24.2M101M88.2M1.5B1.46B785.4M955.4M1.57B1.67B974.6M733.8M34.7M429.4M1.61B781.7M2.03B2.1B957M1.71B1.03B503.3M135.6M000
Accounts Receivable25.23B20.16B13.28B11.34B8.56B8.13B6.93B5.54B5.78B5.26B4.77B4.07B3.8B4.02B3.89B4.24B4.16B3.83B3.28B3.7B2.69B2.76B2.55B2.34B2.07B1.7B1.97B1.84B2.24B1.88B1.74B
Days Sales Outstanding95.02112.87107.58121.25109.45104.75103.0690.6298.196.1681.9874.4670.7363.5362.7963.6965.7764.0558.7272.5762.6868.8367.2467.9568.3453.6166.0767.2488.6686.0590.6
Inventory18.19B13.74B7.59B5.77B4.31B3.89B3.98B3.19B3.1B4.46B3.56B3.45B2.74B2.93B2.64B2.3B2.52B2.85B2.49B2.52B2.27B1.88B2.29B1.96B1.5B1.06B883.1M899.6M999.9M900.7M881.4M
Days Inventory Outstanding407.96453.91329.06297.52237.27193.96264.95246.68241.54365.87227.68249.69202.76217.81201.19165.64210.47244.93207.92216.8233.66197.3259.45267.84250.78179.14198.98198.01239.37228.91242.14
Other Current Assets91M147M111.4M149.5M7.3M0002.23B000000654.9M608.9M271M382.1M642.8M519.2M756.4M255.3M490.4M331.7M223.3M475.6M477.1M667.5M589.3M459.1M
Total Non-Current Assets82.81B56.85B45.98B38.28B31.46B30.35B29.17B25.58B23.36B25.78B23.7B23B24.38B22.14B21.36B19.41B16.16B14.97B16.76B14.56B12.26B13.79B12.03B12.92B11.24B9.5B6.75B5.77B7.19B7.26B10.42B
Property, Plant & Equipment32.19B24.68B17.1B12.91B10.14B8.99B8.68B8.4B8B8.83B8.25B8.05B7.96B7.98B7.76B7.76B7.94B8.2B8.63B8.58B8.15B7.91B7.55B6.54B5.29B4.53B4.18B3.98B4.1B4.1B4.31B
Fixed Asset Turnover3.07x2.64x2.63x2.64x2.81x3.15x2.83x2.66x2.69x2.26x2.57x2.48x2.46x2.90x2.91x3.13x2.91x2.66x2.36x2.17x1.92x1.85x1.84x1.92x2.09x2.55x2.60x2.51x2.25x1.95x1.62x
Goodwill9.87B5.9B5.77B4.94B4.07B3.89B3.77B3.68B1.37B4.37B3.97B4.04B1.76B1.52B1.5B1.43B1.42B1.18B1.17B745.7M00000000000
Intangible Assets18.08B6.52B6.17B6.91B7.21B7.69B7.45B6.62B1.07B4.03B4.36B5.03B2.88B2.81B3.25B3.69B3.39B2.52B2.89B1.71B0000000118.6M1.52B1.55B4.03B
Long-Term Investments13.79B2.8B3.22B3.05B2.9B3.21B2.97B1.96B2.02B5.68B5.21B3.65B4.57B7.62B6.31B4.03B1.78B1.16B1.54B577.1M1B1.3B000000000
Other Non-Current Assets7.7B6.99B5.72B4.99B4.34B4.08B3.48B2.34B8.3B2.87B1.91B2.22B5.74B1.42B1.49B2.49B1.62B1.92B2.15B2.37B3.11B4.58B4.48B6.38B5.94B4.96B2.57B1.67B1.57B1.6B2.08B
Total Assets148.07B112.48B78.71B64.01B49.49B48.81B46.63B39.29B43.91B44.98B38.81B35.57B36.31B35.25B34.4B33.66B31B27.46B29.21B26.79B21.96B24.58B24.87B21.68B19.04B16.43B14.69B12.83B12.6B12.58B14.31B
Asset Turnover0.67x0.58x0.57x0.53x0.58x0.58x0.53x0.57x0.49x0.44x0.55x0.56x0.54x0.66x0.66x0.72x0.74x0.80x0.70x0.70x0.71x0.60x0.56x0.58x0.58x0.70x0.74x0.78x0.73x0.64x0.49x
Asset Growth %143.12%42.89%22.98%29.33%1.4%4.66%18.7%-10.53%-2.38%15.91%9.1%-2.03%3%2.47%2.2%8.58%12.89%-6%9.05%22.01%-10.68%-1.15%14.71%13.84%15.87%11.87%14.55%1.82%0.14%-12.09%-0.73%
Total Current Liabilities47B35.23B28.38B27.29B17.14B15.05B12.48B11.78B11.89B14.54B10.99B8.23B11.21B8.92B8.39B8.93B7.1B6.57B13.11B5.27B5.09B5.72B7.59B5.55B5.06B5.2B4.96B3.94B4.61B4.19B4.22B
Accounts Payable5.79B5.38B3.23B2.6B1.93B1.67B1.61B1.41B1.21B1.41B1.35B1.34B1.13B1.12B1.19B1.13B1.07B968.1M885.8M924.4M789.4M781.3M648.6M875.9M676.9M624.1M661.9M445.5M1.19B985.5M829.3M
Days Payables Outstanding143.89177.65139.99133.94106.2983.38106.95108.6494.11115.7786.2596.9783.4883.2490.4381.0489.6383.273.8779.4181.2482.0873.43119.51113.52105.45149.1498.06283.92250.46227.83
Short-Term Debt2.52B1.64B5.12B6.9B1.5B1.54B8.7M1.5B1.1B3.71B1.94B6.1M2.69B1.01B11.9M1.52B156M27.4M5.85B413.7M219.4M734.7M2.02B196.5M545.4M286.3M184.3M241.5M181.4M227.6M1.21B
Deferred Revenue (Current)0000000000000000000000000000000
Other Current Liabilities12.22B28.21B7.15B4.93B3.91B10.68B9.3B3.1B3.69B7.82B6.61B3.43B3.76B4.72B4.99B5.15B4.56B4.33B5.32B3.06B3.42B3.65B4.45B4.48B3.84B4.29B4.11B3.25B3.24B2.98B2.18B
Current Ratio1.39x1.58x1.15x0.94x1.05x1.23x1.40x1.16x1.73x1.32x1.37x1.53x1.06x1.47x1.55x1.60x2.09x1.90x0.95x2.34x1.91x1.89x1.69x1.58x1.54x1.33x1.60x1.79x1.17x1.27x0.92x
Quick Ratio1.00x1.19x0.89x0.73x0.80x0.97x1.08x0.89x1.47x1.01x1.05x1.11x0.82x1.14x1.24x1.34x1.74x1.47x0.76x1.86x1.46x1.56x1.39x1.22x1.25x1.13x1.42x1.56x0.96x1.05x0.71x
Cash Conversion Cycle359.09389.13296.65284.84240.44215.33261.06228.65245.53346.26223.41227.18190.01198.09173.55148.29186.61225.78192.77209.96215.09184.05253.26216.28205.61127.29115.91167.1944.1164.5104.91
Total Non-Current Liabilities60.8B50.71B36.07B25.85B21.58B24.6B28.33B24.81B21.11B18.78B13.74B12.75B11.18B8.69B11.24B11.19B11.49B11.37B9.37B7.93B5.89B8.07B6.35B6.36B5.7B4.13B3.68B3.88B3.56B3.58B3.98B
Long-Term Debt46.99B40.87B28.53B18.32B14.74B15.35B16.59B13.82B9.2B9.93B8.37B7.97B5.35B4.2B5.52B5.46B6.77B6.63B4.62B4.59B3.49B5.76B4.49B4.69B4.36B3.13B2.63B2.81B2.19B2.33B2.52B
Capital Lease Obligations0000000486.7M000018.5M000000000000000000
Deferred Tax Liabilities5.46B00087.3M1.73B2.1B2.19B1.31B0000000084.8M74.7M287.5M62.2M695.1M620.4M00091.6M137M247.9M215.5M376M
Other Non-Current Liabilities13.82B9.85B7.54B7.53B6.75B7.52B9.64B8.32B10.6B8.85B5.37B4.78B5.85B4.49B5.72B5.73B4.72B4.65B4.68B3.05B2.33B1.61B1.24B1.67B1.35B995M957.9M927.9M1.13B1.04B1.09B
Total Liabilities107.8B85.94B64.44B53.14B38.71B39.65B40.81B36.59B33B33.31B24.73B20.98B20.92B17.61B19.63B20.12B18.59B17.94B22.48B13.37B10.97B13.79B13.95B11.91B10.77B9.33B8.64B7.81B8.17B7.77B8.21B
Total Debt49.5B42.5B33.64B25.23B16.24B16.88B16.6B15.8B10.3B13.65B10.31B7.98B8.06B5.21B5.53B6.99B6.93B6.66B10.46B5.01B3.71B6.5B6.51B4.88B4.9B3.42B2.82B3.05B2.37B2.55B3.73B
Net Debt44.62B35.34B30.38B22.41B14.17B13.07B12.94B13.47B2.98B7.11B5.72B4.31B4.18B1.38B1.51B1.06B933.3M2.2B4.97B1.79B604.5M3.49B1.15B2.13B2.96B716.1M-1.3B-647M871.2M606.2M2.92B
Debt / Equity1.23x1.60x2.36x2.32x1.51x1.84x2.85x5.86x0.94x1.17x0.73x0.55x0.52x0.30x0.37x0.52x0.56x0.70x1.55x0.37x0.34x0.60x0.60x0.50x0.59x0.48x0.47x0.61x0.53x0.53x0.61x
Debt / EBITDA1.18x1.34x1.79x2.05x1.60x1.78x1.94x2.19x1.35x2.35x1.92x1.59x1.71x0.75x0.85x0.91x0.86x0.87x1.57x0.86x0.75x1.49x1.53x1.21x1.28x0.82x0.71x0.80x0.71x0.87x1.44x
Net Debt / EBITDA1.06x1.12x1.62x1.82x1.39x1.38x1.52x1.86x0.39x1.22x1.07x0.86x0.89x0.20x0.23x0.14x0.12x0.29x0.75x0.31x0.12x0.80x0.27x0.53x0.77x0.17x-0.32x-0.17x0.26x0.21x1.13x
Interest Coverage36.14x37.34x21.83x14.49x21.53x19.12x21.11x14.15x16.18x11.24x19.22x18.31x21.16x37.79x31.42x29.76x36.18x21.50x-4.73x------------
Total Equity40.27B26.54B14.27B10.86B10.78B9.15B5.83B2.7B10.91B11.67B14.08B14.59B15.39B17.64B14.77B13.54B12.41B9.53B6.74B13.5B10.98B10.79B10.92B9.76B8.27B7.1B6.05B5.01B4.43B4.81B6.1B
Equity Growth %336.28%85.93%31.37%0.82%17.7%57.16%115.82%-75.26%-6.5%-17.13%-3.49%-5.18%-12.77%19.4%9.15%9.05%30.31%41.42%-50.12%22.98%1.75%-1.17%11.83%18.02%16.46%17.48%20.62%13.17%-7.82%-21.22%12.29%
Book Value per Share45.0829.5515.7912.0311.349.606.092.8210.5511.0912.7913.2013.8615.8012.8912.1511.238.676.1512.3810.109.8710.019.047.646.525.524.533.954.255.46
Total Shareholders' Equity40.27B26.54B14.19B10.77B10.65B8.98B5.64B2.61B9.83B11.59B14.01B14.57B15.37B17.63B14.77B13.54B12.42B9.52B6.74B13.5B10.98B10.79B10.92B9.76B8.27B7.1B6.05B5.01B4.43B4.65B6.1B
Common Stock588M590M592.4M593.6M594.1M596.3M598.2M598.8M661M687.9M688.5M691.3M694.6M698.5M716.6M724.1M721.3M00709.5M0706.9M708M702.3M702.1M702.7M704.4M682M000
Retained Earnings37.97B24.47B13.54B10.31B10.04B8.96B7.83B4.92B11.4B13.89B16.05B16.01B16.48B16.99B16.09B14.9B12.73B9.83B7.65B11.81B10.93B10.03B9.72B9.47B8.5B7.41B6.22B4.99B4.23B4.48B7.21B
Treasury Stock00-49.5M-44.2M-50.5M-52.7M-55.7M-60.8M-69.4M-75.8M-80.5M-90M-91.4M-93.6M-192.4M-95.3M-96.4M-98.5M-99.2M-100.5M-101.4M-104.1M-103.8M-104.2M-109.5M-107.4M-109.5M-108.3M000
Accumulated OCI-2.63B-2.88B-4.32B-4.33B-3.84B-4.34B-9.51B-6.52B-8.74B-8.73B-8.29B-4.58B-3.99B-2B-3.8B-3.86B-2.67B-2.47B-5.51B-2.72B-4.12B-3.16B-2.53B-2.91B-3.43B-3.51B-3.38B-546.3M00-2.79B
Minority Interest0079.5M91.8M125.6M175.6M183.6M92.2M1.08B75.7M72.8M19M14.9M9.3M8.7M-6.1M-7.5M1.6M00000000000160M0

Key Metrics

Growth RegimeExpanding
ProfitabilityStrong
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Leverage rising with debt scaling

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Equity Base Rebuilding Alongside Rising Debt

According to reported quarterly figures, LLY's equity rose from $14.2B in 2024Q2 to $40.3B in 2026Q3, while total assets nearly doubled to $148.1B over the same ten-quarter window.

The balance sheet appears to be strengthening on an absolute basis, driven largely by retained earnings growing from $13.5B to $38.0B. This suggests profits are being retained and reinvested rather than fully distributed, which may indicate management's preference for funding growth internally. Investors should monitor whether this earnings-driven equity build keeps pace with the expanding asset base.

Leverage Elevated but Falling Recently

Based on LLY's reported figures, the debt-to-equity ratio peaked at 2.43 in 2025Q1 before easing to 1.23 in 2026Q3, while total debt climbed to $49.5B from $31.1B in 2024Q3.

The recent improvement in D/E reflects equity growing faster than debt, rather than debt reduction, since total debt remains near multi-year highs. This pattern suggests leverage was taken on to support manufacturing and acquisition activity, with earnings now absorbing it. Refinancing exposure and the cost of servicing a $49.5B debt stack warrant further investigation as rate conditions evolve.

Thin Cash Buffer Against Large Obligations

As reported in financial statements, LLY's cash position fell to $4.9B in 2026Q3 from $8.9B in the prior quarter, while the current ratio held at 1.39, indicating current assets still cover short-term liabilities.

A current ratio above 1.0 provides adequate near-term coverage, but the sharp drop in cash relative to a $148.1B asset base suggests cash has been deployed into operations, capital projects, or acquisitions. The low absolute cash balance relative to total debt may reduce flexibility if earnings soften. This appears to rely on continued operating cash generation for liquidity.

Asset Growth Tilted Toward Manufacturing and Intangibles

According to recent SEC filings, LLY's net PP&E grew from $14.8B to $32.2B over ten quarters, while goodwill expanded from $5.8B to $9.9B, signaling a more capital-intensive and acquisition-linked asset mix.

The PP&E build-out is consistent with the parenteral and fill-finish capacity investment noted in prior analysis, suggesting the business is becoming more asset-heavy. Goodwill growth points to acquired intangibles, which carry impairment risk if acquired products underperform. Taken together, the asset mix may increase sensitivity to both utilization rates and acquisition outcomes.

Equity Growth Masks Concentration Dependence

Based on reported figures, LLY's return on equity of roughly 101% reflects a small and rapidly growing equity base, which may overstate capital efficiency if earnings remain concentrated in the metabolic franchise.

Because equity has expanded substantially through retained earnings, the headline ROE may appear exceptional partly due to the denominator's rapid change and the compressed equity base in earlier periods. The high return is interpretive of a single therapeutic category rather than a diversified earnings base. Investors should monitor whether ROE normalizes as the equity base continues to grow.

LLY — Frequently Asked Questions

Quick answers to the most common questions about buying LLY stock.

What are the total assets of Eli Lilly and Company (LLY)?

As of 2025, Eli Lilly and Company (LLY) had total assets of $112.48B including $55.63B in current assets.

How much debt does Eli Lilly and Company (LLY) have?

Eli Lilly and Company (LLY) carries total debt of $42.50B, offset by $7.27B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Eli Lilly and Company?

Eli Lilly and Company (LLY) has total shareholders' equity (book value) of $26.54B ($29.55 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Eli Lilly and Company's current ratio and liquidity?

Eli Lilly and Company (LLY) reported a current ratio of 1.58x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.